Literature DB >> 24808022

PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy.

Michael D Nelson1, Florian Rader1, Xiu Tang1, Jane Tavyev1, Stanley F Nelson1, M Carrie Miceli1, Robert M Elashoff1, H Lee Sweeney1, Ronald G Victor2.   

Abstract

OBJECTIVE: To determine whether phosphodiesterase type 5 (PDE5) inhibition can alleviate exercise-induced skeletal muscle ischemia in boys with Duchenne muscular dystrophy (DMD).
METHODS: In 10 boys with DMD and 10 healthy age-matched male controls, we assessed exercise-induced attenuation of reflex sympathetic vasoconstriction, i.e., functional sympatholysis, a protective mechanism that matches oxygen delivery to metabolic demand. Reflex vasoconstriction was induced by simulated orthostatic stress, measured as the decrease in forearm muscle oxygenation with near-infrared spectroscopy, and performed when the forearm muscles were rested or lightly exercised with rhythmic handgrip exercise. Then, the patients underwent an open-label, dose-escalation, crossover trial with single oral doses of tadalafil or sildenafil.
RESULTS: The major new findings are 2-fold: first, sympatholysis is impaired in boys with DMD-producing functional muscle ischemia-despite contemporary background therapy with corticosteroids alone or in combination with cardioprotective medication. Second, PDE5 inhibition with standard clinical doses of either tadalafil or sildenafil alleviates this ischemia in a dose-dependent manner. Furthermore, PDE5 inhibition also normalizes the exercise-induced increase in skeletal muscle blood flow (measured by Doppler ultrasound), which is markedly blunted in boys with DMD.
CONCLUSIONS: These data provide in-human proof of concept for PDE5 inhibition as a putative new therapeutic strategy for DMD. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with DMD, PDE5 inhibition restores functional sympatholysis.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24808022      PMCID: PMC4118495          DOI: 10.1212/WNL.0000000000000498

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  Impaired modulation of sympathetic vasoconstriction in contracting skeletal muscle of rats with chronic myocardial infarctions: role of oxidative stress.

Authors:  G D Thomas; W Zhang; R G Victor
Journal:  Circ Res       Date:  2001-04-27       Impact factor: 17.367

2.  Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Denis Duboc; Christophe Meune; Guy Lerebours; Jean-Yves Devaux; Guy Vaksmann; Henri-Marc Bécane
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

3.  Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life.

Authors:  Claudio Ramaciotti; Lisa C Heistein; Melanie Coursey; Matthew S Lemler; Reenu S Eapen; Susan T Iannaccone; William A Scott
Journal:  Am J Cardiol       Date:  2006-08-02       Impact factor: 2.778

4.  Differential sympathetic neural control of oxygenation in resting and exercising human skeletal muscle.

Authors:  J Hansen; G D Thomas; S A Harris; W J Parsons; R G Victor
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

5.  Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy.

Authors:  M Sander; B Chavoshan; S A Harris; S T Iannaccone; J T Stull; G D Thomas; R G Victor
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

6.  Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  R T Moxley; S Ashwal; S Pandya; A Connolly; J Florence; K Mathews; L Baumbach; C McDonald; M Sussman; C Wade
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

7.  Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase.

Authors:  Lie Gao; Wei Wang; Yu-Long Li; Harold D Schultz; Dongmei Liu; Kurtis G Cornish; Irving H Zucker
Journal:  Circ Res       Date:  2004-09-30       Impact factor: 17.367

8.  Differential control of heart rate and sympathetic nerve activity during dynamic exercise. Insight from intraneural recordings in humans.

Authors:  R G Victor; D R Seals; A L Mark
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

Review 9.  Potency, selectivity, and consequences of nonselectivity of PDE inhibition.

Authors:  E Bischoff
Journal:  Int J Impot Res       Date:  2004-06       Impact factor: 2.896

10.  Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.

Authors:  J R Mendell; R T Moxley; R C Griggs; M H Brooke; G M Fenichel; J P Miller; W King; L Signore; S Pandya; J Florence
Journal:  N Engl J Med       Date:  1989-06-15       Impact factor: 91.245

View more
  43 in total

Review 1.  Nitric Oxide Regulates Skeletal Muscle Fatigue, Fiber Type, Microtubule Organization, and Mitochondrial ATP Synthesis Efficiency Through cGMP-Dependent Mechanisms.

Authors:  Younghye Moon; Jordan E Balke; Derik Madorma; Michael P Siegel; Gary Knowels; Peter Brouckaert; Emmanuel S Buys; David J Marcinek; Justin M Percival
Journal:  Antioxid Redox Signal       Date:  2016-08-17       Impact factor: 8.401

Review 2.  Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials.

Authors:  Yuko Shimizu-Motohashi; Shouta Miyatake; Hirofumi Komaki; Shin'ichi Takeda; Yoshitsugu Aoki
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 3.  Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.

Authors:  Dan Li; David J Paterson
Journal:  J Physiol       Date:  2016-05-05       Impact factor: 5.182

4.  Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.

Authors:  Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham
Journal:  Circulation       Date:  2015-05-05       Impact factor: 29.690

5.  Effects of PDE5 inhibition on dystrophic muscle following an acute bout of downhill running and endurance training.

Authors:  Abhinandan Batra; Ravneet S Vohra; Steve M Chrzanowski; David W Hammers; Donovan J Lott; Krista Vandenborne; Glenn A Walter; Sean C Forbes
Journal:  J Appl Physiol (1985)       Date:  2019-04-04

6.  Muscle Decline in Aging and Neuromuscular Disorders - Mechanisms and Countermeasures: Terme Euganee, Padova (Italy), April 13-16, 2016.

Authors: 
Journal:  Eur J Transl Myol       Date:  2016-03-31

Review 7.  Satellite Cells in Muscular Dystrophy - Lost in Polarity.

Authors:  Natasha C Chang; Fabien P Chevalier; Michael A Rudnicki
Journal:  Trends Mol Med       Date:  2016-05-05       Impact factor: 11.951

8.  2015 William Allan Award.

Authors:  Kay E Davies
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

9.  Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy.

Authors:  Ulrich Lindberg; Nanna Witting; Stine Lundgaard Jørgensen; John Vissing; Egill Rostrup; Henrik Bo Wiberg Larsson; Christina Kruuse
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  Skeletal Muscle Neurovascular Coupling, Oxidative Capacity, and Microvascular Function with 'One Stop Shop' Near-infrared Spectroscopy.

Authors:  Ryan Rosenberry; Susie Chung; Michael D Nelson
Journal:  J Vis Exp       Date:  2018-02-20       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.